Herlev Hospital

Running trials

• Not yet recruiting

  Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer

  NCT07903883· Source

• Recruiting

  A randomised active-controlled study to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation

  2026-525417-31-00· Phase 2· Source

• Recruiting

  A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

  NCT07672236· Phase 3· Source

• Recruiting

  Neoadjuvant nivolumab and ipilimumab for patients with high-risk uveal melanoma

  2025-524953-15-00· Phase 1· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Source

• Recruiting

  Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

  NCT06892210· Phase 4· Source

• Not yet recruiting

  Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer

  NCT07409844· Phase 2· Source

• Recruiting

  An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

  NCT07206056· Phase 1/2· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Source

• Recruiting

  [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer

  NCT07215182· Phase 2· Source

• Recruiting

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· Phase 3· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· Source

• Recruiting

  Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419/ANV600) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL

  2023-506400-99-00· Phase 2· Source

• Recruiting

  T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

  NCT06783270· Phase 1· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

  NCT06534983· Phase 2· Source

• Active, not recruiting

  Continuous Glucose Monitoring in Dialysis Patients With Diabetes

  NCT06641765· Source

• Recruiting

  Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload

  NCT06166654· Phase 3· Source

• Recruiting

  ADP-TILIL7

  2023-509665-20-00· Phase 1· Source

• Active, not recruiting

  A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alterations.

  2023-507684-19-00· Phase 3· Source

• Active, not recruiting

  Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

  NCT06353386· Phase 1/2· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Source

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Source

• Recruiting

  DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure

  NCT05276219· Phase 4· Source

• Recruiting

  Rescue of Nephrons With ALE.F02 (RENAL-F02)

  NCT06047171· Phase 2· Source

• Recruiting

  Does peri-operative treatment with Tranexamic Acid reduce the early relapse rate for patients with melanoma; a randomised controlled trial

  2022-502633-26-00· Phase 3· Source

• Recruiting

  GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer

  NCT06111105· Source

• Recruiting

  DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies

  NCT06076811· Source

• Active, not recruiting

  A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

  NCT05933577· Phase 3· Source

• Enrolling by invitation

  Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

  NCT05707949· Phase 3· Source

• Recruiting

  A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

  NCT05711394· Phase 3· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Source

• Active, not recruiting

  IMPROVE-pT1: Accurate Allocation of Completion Resection in Early Colorectal Cancer

  NCT06040632· Source

• Enrolling by invitation

  Translating Genetic Knowledge Into Clinical Care in Non-Autoimmune Diabetes

  NCT05368220· Source

• Active, not recruiting

  The Diverticulitis Study

  NCT06023004· Source

• Recruiting

  A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma

  NCT05203120· Source

• Recruiting

  Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors

  NCT04916132· Source

• Active, not recruiting

  Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

  NCT04688788· Phase 3· Source

• Active, not recruiting

  A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

  NCT04736706· Phase 3· Source

• Recruiting

  BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

  NCT04752826· Phase 1/2· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

  NCT04634877· Phase 3· Source

• Active, not recruiting

  A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

  NCT04607421· Phase 3· Source

• Active, not recruiting

  A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

  NCT04616326· Phase 3· Source

• Active, not recruiting

  A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

  NCT04557059· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

  NCT04546009· Phase 3· Source

• Active, not recruiting

  High Intensity Aerobic Exercise Training and Immune Cell Mobilization in Patients With Lung Cancer (HI AIM)

  NCT04263467· Source

• Recruiting

  The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer

  NCT04291378· Source

• Active, not recruiting

  Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

  NCT04138628· Phase 2· Source

• Active, not recruiting

  ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial

  NCT04084249· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Melanoma6 recruiting
• Colorectal cancer4 recruiting
• Heart failure4 recruiting
• Chronic kidney disease3 recruiting
• Prostate cancer3 recruiting
• Atrial fibrillation2 recruiting
• Bladder cancer2 recruiting
• Crohn's disease2 recruiting
• Lung cancer2 recruiting
• Migraine2 recruiting
• Type 2 diabetes2 recruiting
• Cervical cancer1 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Ovarian cancer1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  ARIISE - ASCs in recently diagnosed non-ischemic heart failure

  NCT06840275· Phase 2· Source

• Active, not recruiting

  Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  2023-503428-24-00· Phase 2· Source

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

  NCT06132958· Phase 3· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Source

• Completed

  Orismilast for the treatment of moderate to severe ulcerative colitis

  2022-502763-37-02· Phase 2· Source

• Completed

  A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.

  2022-502789-26-01· Phase 2· Source

• Completed

  Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors

  2022-502787-20-00· Phase 2· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Source

• Completed

  Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis

  NCT04987307· Phase 2· Source

• Completed

  A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Participants with BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with Central Nervous System Metastases

  2023-506310-43-00· Phase 1· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

  NCT05173987· Phase 3· Source

• Completed

  Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

  NCT05002569· Phase 3· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· Source

• Completed

  A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

  NCT05093933· Phase 3· Source

• Completed

  A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

  NCT05047263· Phase 3· Source

• Completed

  The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure

  NCT05084235· Phase 2· Source

• Completed

  The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

  NCT05042973· Phase 2· Source

• Completed

  HOLT-ED: Holter-monitoring in End-stage Renal Disease

  NCT04876963· Source

• Completed

  When to INDuce for OverWeight? (WINDOW)

  NCT04603859· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Source

• Completed

  Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC

  NCT04191096· Phase 3· Source

• Active, not recruiting

  A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

  NCT04008030· Phase 3· Source

• Completed

  Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

  NCT03924856· Phase 3· Source

• Completed

  Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy

  NCT03740126· Source

• Completed

  A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

  NCT03708328· Phase 1· Source

• Completed

  A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations, HOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups

  NCT03226301· Phase 2· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· Source

• Completed

  Quality of Life the Danish Multiple Myeloma Patients

  NCT02892383· Source

• Completed

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· Phase 3· Source

• Completed

  Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

  NCT02231749· Phase 3· Source

• Completed

  An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

  NCT01968109· Phase 1/2· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Source